Orchestra BioMed Holdings, Inc. (OBIO)
(Delayed Data from NSDQ)
$2.44 USD
-0.07 (-2.79%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $2.43 -0.01 (-0.41%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
11/11/2025
Time: -- |
9/2025 | $-0.45 | 12.22% |
Earnings Summary
For their last quarter, Orchestra BioMed Holdings, Inc. (OBIO) reported earnings of -$0.50 per share, beating the Zacks Consensus Estimate of $-0.51 per share. This reflects a positive earnings surprise of 1.96%. Look out for OBIO's next earnings release expected on November 11, 2025. For the next earning release, we expect the company to report earnings of -$0.45 per share, reflecting a year-over-year decrease of 9.76%.
Earnings History
Price & Consensus
Zacks News for OBIO
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates
OBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
OBIO FAQs
Based on past history, Zacks believes Orchestra BioMed Holdings, Inc. (OBIO) will report their next quarter earnings on November 11, 2025. For the next earning release, we expect the company to report earnings of -0.45 per share, reflecting a year-over-year increase of -9.76.
Based on past history, Zacks believes Orchestra BioMed Holdings, Inc. (OBIO) will report their previous quarter earnings %%TIME_OF_DAY_CODE%% on November 11, 2025.
The Zacks Consensus Estimate for Orchestra BioMed Holdings, Inc. (OBIO) for the quarter ending in September 2025 is $-0.45 a share. We expect Orchestra BioMed Holdings, Inc. to miss by 12.22%.
In the earnings report for the quarter ending in June 2024, Orchestra BioMed Holdings, Inc. (OBIO) announced earnings of $-0.45 per share versus the Zacks Consensus Estimate of $-0.41 per share, representing a surprise of 9.76%.